checkAd
    Startseite > Aktien > Cullinan Oncology > Nachrichten
    Cullinan Oncology
    Aktie
    ISIN: US2300311063 WKN: A2QL3C SYM: CGEM Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    23,250
     
    USD
    +0,280 USD
    +1,22 %
    Letzter Kurs 02:00:00 Nasdaq
    Geldkurs
    11.06.24
    23,190
     
    USD
    500 STK
    Briefkurs
    11.06.24
    23,250
     
    USD
    3.200 STK

    Cullinan Oncology Aktie kaufen

    Kauf
    Verkauf
    ISIN: US2300311063 WKN: A2QL3C SYM: CGEM Land USA

    Neueste Nachrichten

    Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
    01.06.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
    24.05.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
    23.05.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
    15.05.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
    29.04.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
    24.04.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
    16.04.24 · globenewswire · Cullinan Oncology
    Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
    16.04.24 · globenewswire · Cullinan Oncology
    Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    14.03.24 · globenewswire · Cullinan Oncology
    Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
    01.03.24 · globenewswire · Cullinan Oncology
    Cullinan Oncology to Participate in Upcoming Investor Conferences
    27.02.24 · globenewswire · Cullinan Oncology
    Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    18.12.23 · globenewswire · Cullinan Oncology